KYTHERA Biopharmaceuticals to Present at Leerink Swann 2012 Global Healthcare Conference

LOS ANGELES--(BUSINESS WIRE)-- KYTHERA Biopharmaceuticals, Inc. (KYTHERA), a privately held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, announced today that Keith Leonard, President and Chief Executive Officer, will present a corporate overview at the Leerink Swann 2012 Global Healthcare Conference in New York City.



Leerink Swann 2012 Global Healthcare Conference


Wednesday, February 15, 2012


10:30 a.m. ET

About KYTHERA Biopharmaceuticals, Inc.

KYTHERA Biopharmaceuticals, Inc. is a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic market. KYTHERA’s lead clinical program, ATX-101, is focused on the reduction of submental (under the chin) fat. The company also has active research programs with focused interest in hair and fat biology, pigmentation modulation and facial contouring. Find more information at


KYTHERA Biopharmaceuticals, Inc.
Investor Contact: Heather Rowe
Tel: (818) 587-4559
[email protected]
Media Contact: Erica Bazerkanian
Tel: (805) 300-9289
[email protected]

KEYWORDS:   United States  North America  California  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health  General Health



Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.